Drug Channels Archive

Individual mailing archives are available to subscribers only.

Recent

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

Click a link below to view the mailing archive as if it had been sent to you.

2026-10-09 07:47		Drug Channels - Transparency is No Longer a Compliance Issue
2026-10-08 07:47		Drug Channels - The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)
2026-10-07 07:47		Drug Channels - 2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges (rerun)
2026-10-06 07:47		Drug Channels - Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains (rerun)
2026-10-05 07:47		Drug Channels - Informa's PBM Contracting Summit
2026-10-02 07:47		Drug Channels - Patient Support Strategy by Lifecycle Stage: Launch, Growth, Maturity, and Loss of Exclusivity
2026-09-29 07:47		Drug Channels - Drug Channels News Roundup, September 2026: The 340B Margin Squeeze, Economics of Cutting List Price, Patient Adherence from Copay Cards, Negative Part D Premiums, and Drug Channel Dating Profiles
2026-09-25 07:47		Drug Channels - Why GoodRx Is Built for the AI-Driven Patient Journey
2026-09-22 07:47		Drug Channels - The Spinoff: How Biosimilars Are Becoming Wholesalers' Next Hit Show
2026-09-21 07:47		Drug Channels - Keep Your Patient Program at the Forefront of Innovation at Patient Pathways: The Copay and Patient Services Congress
2026-09-18 07:47		Drug Channels - Fixing the Front Door Isn't the Same as Fixing Time to Therapy
2026-09-15 07:47		Drug Channels - Preorder DCI's New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
2026-09-14 07:47		Drug Channels - Informa Connect's Pharma/Biotech GTN Summit
2026-09-09 07:47		Drug Channels - Drug Channels Leadership Forum 2027: Antonio Ciaccia to Serve as Moderator
2026-09-03 07:47		Drug Channels - BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
2026-09-01 07:47		Drug Channels - The Private Label Biosimilar Paradox in Medicare Part D

Please enter all required fields

Correct invalid entries

Subscribe >>